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Introduction

Methods

Recruitment and activation of PMNs and subsequent SO release
contribute to inflammation mediated tissue injury such as that following
ischemia/reperfusion (I/R). Therefore, identifying mechanisms that
regulate PMN SO release may lead to therapies that mitigate PMN tissue
injury. Phosphorylation of PMN NADPH oxidase by PKC is essential to
generate SO release. There are 5 isoforms of PKC (alpha (α), beta I (βI),
beta II (βII), delta (δ), and zeta (ζ)) expressed by PMNs which regulate
NADPH oxidase activity by phosphorylation of p47phox (a component of
the NADPH oxidase enzyme) (figure 1). It is known that PMA, a broadspectrum PKC activator which functions as a diacylglycerol (DAG)
mimetic, augments SO release in PMNs via NADPH oxidase activation
principally through βII, ζ, and to a lesser extent α activation [1].
Additionally, PKC δ activation is known to inhibit PMN elastase release
which occurs during inflammation of activated PMNs [2]. To date, the
roles of PKC δ in mediating inflammatory responses and leukocyte SO
release in vivo remains unclear. Characterizing the role of various PKC
isoforms would help elucidate the homeostatic balance of PKC regulating
PMN NADPH oxidase and inflammation mediated I/R injury.
We have previously shown that a cell-permeable PKC δ peptide activator
(PKC δ+) facilitates the translocation of PKC δ to cell substrates via
interaction with its specific receptor for activated C kinase (RACK)
exhibited cardioprotection in a leukocyte aggravated myocardial I/R
injury ex vivo model and attenuated NG-nitro-L-arginine-methyl-ester (LNAME) induced leukocyte endothelial interactions in mensenteric
venules in vivo [3]. We speculate that PKC δ activation may also
negatively regulate PMN SO release. Moreover, Inagaki et al, showed
that activation of PKC δ mediates cardioprotective effects in myocardial
I/R injury [4]. We propose that inhibiting PKC δ would augment PMN
SO release. Therefore, using a PKC δ peptide inhibitor (PKC δ-) that
inhibits the binding of PKC δ to its RACK, or rottlerin, a phenolic
compound that is a selective inhibitor of PKC δ (IC50 3-6 µM) at its ATP
binding site can be used to assess the role of PKC δ in the regulation of
SO release in PMNs [5,6,7].

Isolation of PMNs
Male Sprague-Dawley rats (350-400 g, Charles River), used as PMN
donors, were anesthetized with 2.5% isoflurane and given a 16 ml
intraperitoneal injection of 0.5% glycogen (Sigma Chemical) dissolved
in PBS. Rats were reanesthetized with isoflurane 16-18 h later, and the
PMNs were harvested by peritoneal lavage in 30 ml of 0.9% NaCl, as
previously described [5,8]. Peritoneal lavage fluid was centrifuged at
200 x g for 10 min at 4°C. Then, the PMNs were washed in 20 ml PBS
and centrifuged at 200 g for 10 min at 4° C. PMNs were resuspended in
2.5 mL PBS and density was calculated. The PMNs preparation were
>90% pure and >95% viable according to microscopic analysis and 0.3
trypan blue exclusion, respectively.
Measurement of SO release from Rat PMNs
The SO release from PMNs was measured spectrophotometrically
(model 260 Gilford, Nova Biotech; El Cajon, CA) by the reduction of
ferricytochrome c [5,8]. The PMNs (5 x 106) were resuspended in 450 µl
of PBS and incubated with ferricytochrome c (100 µM, Sigma
Chemical) in a total volume of 900 µl PBS in the presence or absence of
PKC δ activator (Myr-MRAAEDPM, MW=1130 g/mol, 2.5-20 µM,
n=10-13), PKC δ inhibitor (Myr-SFNSYELGSL, MW=1326 g/mol, 1-20
µM, n=7-10) or rottlerin (MW=516 g/mol, 0.625-20 µM, n=8-12) for 15
min at 37°C in spectrophotometric cells. The PMNs were stimulated
with 15 or 30 nM PMA (MW=616 g/mol, n=13-26) in a final reaction
volume of 1.0 ml. Absorbance at 550 nm was measured every 30 sec for
up to 420 sec for PMA and the change in absorbance (SO release) from
PMNs was determined relative to time 0. Cell viability among all study
groups was determined by 0.3% trypan blue exclusion at the end of SO
release assay. Viable cells remained unstained and non-viable cells
stained blue.
Statistical Analysis
All data in the text and figures are presented as means ± S.E.M. The
data were analyzed by analysis of variance using post hoc analysis with
Fishers PLSD test. Probability values of <0.05 are considered to be
statistically significant.

Results

Figure 5. Time course of PMA (30 nM) induced SO release in presence and

absence of varying concentrations of PKC δ+
PKC δ peptide activator dose-dependently inhibited PMA induced SO release by
48±12% (10 μM ) and 50±7% (20 μM) (both p<0.05 vs untreated controls) at 7
min respectively.

Figure 6. The effects of rottlerin, PKC δ peptide inhibitor, and PKC δ peptide
activator (all 10 and 20 μM) on cell viability in PMA induced SO release assays.
Untreated PMA controls, PKC δ peptide inhibitor, and PKC δ peptide activator
showed 95±1% cell viability after SO release cell measurements. Rottlerin showed
91±1% (10 μM) and 89±2% (20 μM) cell viability after SO release cell
measurements. Lower doses of rottlerin that also showed significant augmentation
in PMA SO release (see figure 3), had cell viability values 94±1%.

Conclusions and Future Research

Figure 1. Inflammatory cytokines bind to PMN chemotactic receptors signaling
PKC activation via DAG. p47phox is phosphorylated by multiple PKC isoforms
that can augment (α/βII/ζ) or inhibit (δ) the assembly of cytosolic subunits to the
membranous components of NADPH oxidase leading to activation or inhibition of
activity. PKC δ+, a cell-permeable peptide, increases the translocation of PKC δ to
cell substrates such as p47phox. PKC δ phosphorylation of PMN p47phox is
associated with negative regulation preventing the assembly NADPH oxidase and
thereby inhibiting SO (O2-) release. By contrast, inhibiting PKC δ phosphorylation
Figure 3. Time course of PMA (30 nM) induced SO release in presence and
of p47phox with rottlerin or PKC δ- would augment PMA induced SO release.

absence of varying concentrations of rottlerin

Rottlerin dose-dependently augmented PMA induced SO release by 96±9% (10
μM). The 20 μM dose augmented PMA induced SO release by 83±6% at 7 min
(both p<0.05 compared to untreated control) at 7 min respectively.

Figure 2. Illustration of the mechanism and amino acid (aa) sequence of PKC δ
isoform activator/inhibitor peptides, PKC δ inhibitor rottlerin, and the broadspectrum PKC activator PMA. The RACK-1 region is unique for PKC δ and is
responsible for regulating the translocation of PKC δ from the cytosol to the cell
membrane. The inhibitory region attenuates interaction of activated PKC δ for its
RACK whereas the activator peptide augments interaction with PKC δ and its
RACK. Both peptides are conjugated to myristric acid (Myr) at the N-terminus to
facilitate cell permeability. Rottlerin is a lipid-soluble phenolic compound derived
from the Mallotus philippinensis tree that is selective for inhibiting PKC δ at its ATP
binding site. Finally, PMA is a lipid-soluble PKC agonist at the regulatory domain.

Hypothesis

As expected, PKC δ+ attenuated PMN SO release up to 50%, whereas,
rottlerin augmented the PMA response up to 96% compared to untreated
PMA controls (both p<0.05). However, the PKC δ- only enhanced PMN
SO release up to 30%. Moreover, cell viability was >93±4% in all study
groups suggesting that the effects of rottlerin, PKC δ-, and PKC δ+ on
PMA induced SO release were not related to cell viability. The data
suggest that PKC δ negatively regulates PMN NADPH oxidase SO
release. PKC δ- is relatively ineffective in regulating PMN SO release
compared to rottlerin. The data suggest that inhibiting the ATP binding
site of PKC δ by rottlerin may be more effective than the inhibition of
the translocation of PKC δ to PMN substrates such as NADPH oxidase.
Preliminary data shows that superoxide dismutase (SOD) inhibited
untreated PMA (30 nM, n=3) induced SO release by 95±9% and also
attenuated PMA plus rottlerin (20 μM, n=3) induced SO release by
96±4%. Cell viability was 96±1% in SOD treated groups. These
preliminary results suggests that the effects of rottlerin to augment the
reduction of ferricytochrome c in the presence of PMA are related to the
generation of SO release. Additional trials will be preformed to confirm
the preliminary results. Further research will be aimed at determining the
phosphorylation sites of p47phox by PKC δ.
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